Xie Xuemeng, Zhang Jincheng, Chen Di, Pan Hao, Wu Ziqian, Ge Dong, Yang Guangtian
Departments of *Emergency, and †Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China.
Shock. 2015 May;43(5):490-6. doi: 10.1097/SHK.0000000000000337.
Poor neurological outcome remains a major problem in patients with cardiac arrest. Ghrelin has been shown to be neuroprotective in models of neurologic injury in vitro and in vivo. This study was performed to assess the effects of ghrelin on postresuscitation brain injury in a rat model of cardiac arrest. Sprague-Dawley rats were subjected to 6-min cardiac arrest and resuscitated successfully. Either vehicle (saline) or ghrelin (80 μg/kg) was injected blindly immediately after return of spontaneous circulation (ROSC). A tape removal test was performed to evaluate neurological function at 24, 48, and 72 h after ROSC. Then, brain tissues were harvested and coronal brain sections were analyzed by hematoxylin and eosin (HE) staining for neuronal viability and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining for apoptosis in hippocampal CA1 sectors. In additional groups, rats were sacrificed at 6 h after ROSC, and hippocampal tissues were collected for further analysis. We found that animals treated with ghrelin had improved neurological performances, reduced neuronal injury, and inhibited neuronal apoptosis compared with the vehicle group. Moreover, ghrelin treatment was associated with the following: (1) a decrease in caspase-3 up-regulation and an increased Bcl-2/Bax ratio, (2) a reduction in maleic dialdehyde content and an up-regulation in superoxide dismutase activity, and (3) an increase in uncoupling protein 2 (UCP-2) expression. Our results suggest that ghrelin treatment attenuated postresuscitation brain injury in rats, possibly via regulation of apoptosis, oxidative stress, and mitochondrial UCP-2 expression. Ghrelin may have therapeutic potential when administered after cardiac arrest and cardiopulmonary resuscitation.
神经功能预后不良仍是心脏骤停患者面临的主要问题。在体外和体内神经损伤模型中,胃饥饿素已被证明具有神经保护作用。本研究旨在评估胃饥饿素对心脏骤停大鼠模型复苏后脑损伤的影响。将Sprague-Dawley大鼠进行6分钟的心脏骤停并成功复苏。自主循环恢复(ROSC)后立即盲目注射溶媒(生理盐水)或胃饥饿素(80μg/kg)。在ROSC后24、48和72小时进行胶带去除试验以评估神经功能。然后,采集脑组织,并用苏木精和伊红(HE)染色分析冠状脑切片以评估神经元活力,用末端脱氧核苷酸转移酶介导的dUTP缺口末端标记染色评估海马CA1区的细胞凋亡。在其他组中,大鼠在ROSC后6小时处死,收集海马组织进行进一步分析。我们发现,与溶媒组相比,接受胃饥饿素治疗的动物神经功能表现改善,神经元损伤减少,神经元凋亡受到抑制。此外,胃饥饿素治疗与以下情况相关:(1)半胱天冬酶-3上调减少而Bcl-2/Bax比率增加;(2)丙二醛含量降低而超氧化物歧化酶活性上调;(3)解偶联蛋白2(UCP-2)表达增加。我们的结果表明,胃饥饿素治疗可减轻大鼠复苏后脑损伤,可能是通过调节细胞凋亡、氧化应激和线粒体UCP-2表达来实现的。在心脏骤停和心肺复苏后给予胃饥饿素可能具有治疗潜力。